BASF and Sumitomo Chemical explore in vitro system for chemical safety evaluation
![](/46/pdcnewsitem/03/84/59/BASF.png)
Application of fully functional cultured cells as alternative to animal testing.
Sumitomo Chemical Co. and BASF have agreed to collaborate on research into a more sustainable, in vitro system for chemical safety evaluation.
Recent years have seen an increase in stringent regulations for registration of agricultural chemicals and pharmaceuticals, and the demand to increase human relevance of safety studies. For these reasons, Sumitomo Chemical and BASF aim to create a system that supports the development of safe chemicals, while reducing the need for conventional animal testing.
As the first step in their research, Sumitomo Chemical and BASF aim to establish a new line of fully functional cultured cells to enable the safety evaluation of chemicals in a more efficient and more precise way than conventional methods.
Dr Peter Eckes, President of BASF Bioscience Research, said: “BASF celebrates its 150th anniversary this year, and we have a history of continuous commitment to sustainability throughout our operations. In this collaboration we are combining the strength of both companies to develop new methods to reduce animal testing.”
Ikuzo Ogawa, Managing Executive Officer of Sumitomo Chemical in charge of technology and research and development, said: “We will contribute to building a sustainable society through supplying safer chemicals. We are very delighted to work on the collaborative research of such great social significance in the year marking the 100th anniversary of the start of Sumitomo Chemical’s operations.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance